Valiloxybate - XWPharma
Alternative Names: XW-10172Latest Information Update: 04 Apr 2025
At a glance
- Originator XW labs
- Developer XWPharma
- Class Neuroprotectants; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Narcolepsy
Most Recent Events
- 25 Mar 2025 XWPharma withdrawn phase II trial prior to enrolment in Parkinson's disease due to sponsor decision (NCT05056194)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers, In adults) in Australia (PO, Controlled release)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers, In adults) in Australia (PO, Immediate release)